Selegiline transdermal - Somerset Pharmaceuticals

Drug Profile

Selegiline transdermal - Somerset Pharmaceuticals

Alternative Names: Emsam

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Somerset Pharmaceuticals
  • Class Analgesics; Antidementias; Antidepressants; Antiparkinsonians; Phenethylamines; Small molecules
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Major depressive disorder
  • No development reported Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease

Most Recent Events

  • 29 May 2009 Selegiline is no longer licensed to Bristol-Myers Squibb in USA; Dey LP aquires marketing rights
  • 28 Jul 2008 Somerset Pharmaceuticals has become a wholly owned subsidiary of Mylan Inc.
  • 08 May 2008 Efficacy data from a post-hoc analysis in Depression presented at the 161st Annual Meeting of the American Psychiatric Association (APA-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top